P Ren1, J-G Zhang, L Xiu, Z-T Yu. 1. Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital and Key Laboratory of Cancer Prevention and Therapy, TianJin, China. renpengtj@126.com
Abstract
AIM: The aim of this study was to clarify the clinico-pathological outcome and prognostic significance of phospholipase A2 group IIA (PLA2G2A) in esophageal squamous cell carcinoma (ESCC). PATIENTS AND METHODS: Immunohistochemical staining for PLA2G2A was performed on surgical specimens obtained from 132 patients with ESCC, and 43 from matched adjacent non-malignant sites. Differences in PLA2G2A expression and clinical characteristics were compared by χ2 test. Correlations between prognostic outcomes and with PLA2G2A expression were investigated using Kaplan-Meier analysis and the Cox proportional hazards model. RESULTS: Immunoreactivity of PLA2G2A was observed in 32% (42 of 132) of ESCC tissues compared with negative staining in matched adjacent non-malignant sites. In addition, PLA2G2A expression inversely correlated with pathological classification (p < 0.05 for T, N, and M classifications) and clinical staging (p = 0.03). Furthermore, patients with positive PLA2G2A had prolonged overall survival (p < 0.01). CONCLUSIONS: Reduced PLA2G2A expression may be a risk factor for advanced clinicopathological classification and poor patient survival. These findings suggest that PLA2G2A may serve as a useful marker for the prognostic evaluation of ESCC patients.
AIM: The aim of this study was to clarify the clinico-pathological outcome and prognostic significance of phospholipase A2 group IIA (PLA2G2A) in esophageal squamous cell carcinoma (ESCC). PATIENTS AND METHODS: Immunohistochemical staining for PLA2G2A was performed on surgical specimens obtained from 132 patients with ESCC, and 43 from matched adjacent non-malignant sites. Differences in PLA2G2A expression and clinical characteristics were compared by χ2 test. Correlations between prognostic outcomes and with PLA2G2A expression were investigated using Kaplan-Meier analysis and the Cox proportional hazards model. RESULTS: Immunoreactivity of PLA2G2A was observed in 32% (42 of 132) of ESCC tissues compared with negative staining in matched adjacent non-malignant sites. In addition, PLA2G2A expression inversely correlated with pathological classification (p < 0.05 for T, N, and M classifications) and clinical staging (p = 0.03). Furthermore, patients with positive PLA2G2A had prolonged overall survival (p < 0.01). CONCLUSIONS: Reduced PLA2G2A expression may be a risk factor for advanced clinicopathological classification and poor patient survival. These findings suggest that PLA2G2A may serve as a useful marker for the prognostic evaluation of ESCC patients.
Authors: Ping-Ching Hsu; Renny S Lan; Theodore M Brasky; Catalin Marian; Amrita K Cheema; Habtom W Ressom; Christopher A Loffredo; Wallace B Pickworth; Peter G Shields Journal: Mol Carcinog Date: 2016-08-22 Impact factor: 4.784
Authors: Erin M Siegel; Steven Eschrich; Kathryn Winter; Bridget Riggs; Anders Berglund; Abidemi Ajidahun; Jeff Simko; Jennifer Moughan; Jaffer Ajani; Anthony Magliocco; Abul Elahi; Sarah Hoffe; David Shibata Journal: Dis Colon Rectum Date: 2014-08 Impact factor: 4.585
Authors: Mahboube Shariati; Mahmoud Aghaei; Ahmad Movahedian; Mohammad Hosein Somi; Homayun Dolatkhah; Ahmad Mirza Aghazade Journal: J Res Med Sci Date: 2016-02-23 Impact factor: 1.852